<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00787722</url>
  </required_header>
  <id_info>
    <org_study_id>DIAD Devic's Disease Auto 2008</org_study_id>
    <nct_id>NCT00787722</nct_id>
  </id_info>
  <brief_title>Hematopoietic Stem Cell Transplant in Devic's Disease</brief_title>
  <official_title>Trial of High Dose Immunosuppressive Therapy With Hematopoietic Stem Cell Support in Devic's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to examine whether treating Devic's disease patients with high dose
      cyclophosphamide together with rabbit antithymocyte globulin (rATG)/rituximab (drugs which
      reduce the function of the immune system), followed by return of previously collected
      patient's stem cells will result in improvement in Devic's disease. Stem cells are
      undeveloped cells that have the capacity to grow into mature blood cells, which normally
      circulate in the blood stream. The purpose of the intense chemotherapy is to destroy the
      cells in patient's immune system, which may be causing his/her disease. The purpose of the
      stem cell infusion is to produce a normal immune system that will no longer attack patient's
      body. The purpose of study is to examine the safety and efficacy of this treatment. The drugs
      used in this study treatment are drugs for commonly used for immune suppression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Neuromyelitis optica (NMO, Devic's disease) is an autoimmune, inflammatory, demyelinating
      central nervous system disorder in which a person's own immune system attacks the optic
      nerves and spinal cord and is characterized by concurrence of optic neuritis and transverse
      myelitis, typically associated with a lesion in the spinal cord extending over three or more
      vertebral segments. Although it is most commonly relapsing, it is distinct from multiple
      sclerosis in that it is more severe, tends to spare the brain, and is associated with a
      longitudinally extensive lesion on spinal cord MRI. Furthermore, NMO is associated with a
      highly specific serum autoantibody marker, NMO-immunoglobulin G (IgG), which targets the
      water channel aquaporin-4. The disease follows a relapsing course in more than 90% of
      patients.

      At present, parenteral corticosteroids are widely employed as first-line treatment of optic
      neuritis and myelitis attacks, whereas therapeutic plasmapheresis is applied in the case of
      corticosteroids failure. Various strategies for the prevention of NMO relapses have been
      employed in small case series with modest activity. Immune based therapies, in order to be
      effective, need to be started early in the disease course while Devic's disease is
      predominantly an immune-mediated and inflammatory disease. Since 50% of patients with NMO are
      confined to a wheelchair within 5 years of onset, new therapies are needed in this disease.

      We now propose, as a phase I study, complete immune ablation and subsequent reconstitution
      with autologous stem cells.

      Based on the experience of the pilot studies, the current protocol will mobilize stem cells
      with granulocyte-colony stimulating factor (G-CSF) and cyclophosphamide and collect stem
      cells by apheresis. A subsequent bone marrow harvest will be performed only if needed to
      supplement the peripheral blood stem cells (PBSC). Based on experience of autoimmune flares
      in patients receiving G-CSF alone for mobilization, patients will be mobilized with
      cyclophosphamide 2.0 g/m2 and G-CSF 5- 10 mcg /kg.

      In order to avoid cumulative cardiac toxicity from cyclophosphamide and to allow culture of
      hematopoietic stem cell (HSC) product, three weeks must separate the administration of
      cyclophosphamide for mobilization and for conditioning.

      Cyclophosphamide 50 mg/kg/day will be given IV over 2 hours in 500 cc of normal saline. If
      actual weight is &lt; ideal weight, cyclophosphamide will be given based on actual weight. If
      actual weight is &gt; ideal weight, cyclophosphamide will given as adjusted weight. Adjusted
      weight = ideal weight + 25% (actual weight minus ideal weight).

      Hydration-guidelines, normal saline (NS) at 150-200 ml/hr should be given 2 hours before
      cyclophosphamide and continued until 24 hours after the last cyclophosphamide dose. The rate
      of hydration will be aggressively adjusted. Twice daily weights will be obtained. Amount of
      fluid can be modified based on patient's fluid status.

      r ATG 0.5 mg/kg given on day -5, then 1.0 mg/kg given on day -4, then 1.5 mg/kg given on days
      -3 through -1. rATG is infused over 10 hours. Premedicate with Acetaminophen 650 mg po and
      Diphenhydramine 25 mg po/IV 30 minutes before the infusion.

      Rituxan ( Rituximab ) - The dose of 500 mg of Rituximab will be diluted in 500 ml 0.9 % NS
      and infused per standard Rituximab infusion guidelines, given on days -6 and on day + 1.
      Following the guidelines, Rituximab will be started at 50 mg/hr. If no reaction occurs, the
      dose will be increased by 50 mg/hr every 30 minutes to a maximum of 400 mg/hr.

      G-CSF - guidelines, 5-10 mcg/kg/day will be started day + 5 and continued until the absolute
      neutrophil counts reaches at least 1,000/Âµl.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 10, 2009</start_date>
  <completion_date type="Actual">November 2018</completion_date>
  <primary_completion_date type="Actual">November 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>6 months, 1 year, 2 year, 3 year, 4 year, 5 year - after the transplant</time_frame>
    <description>survival rate will be evaluated at 6 months,1 year, 2 year, 3 year, 4 year, 5 year after the transplant</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QOL) Short Form - 36 (SF-36)</measure>
    <time_frame>pre-transplant 12mo and 5 years</time_frame>
    <description>SF- 36 is a self-administered quality of life exam. The evaluation of the results was done by attributing scores to each question, which were then transformed into a scale ranging from 0 to 100, where 0 corresponds to the worst quality of life and 100 to the best.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post HSCT Immune -Modulating Medication and Relapse</measure>
    <time_frame>Pre transplant and 6 months, 1 year, 2 year, 3 year, 4 year and 5 year after transplant</time_frame>
    <description>Number of immune - modulating medication and relapse evaluated 5 year - after the transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Require No Device Assistance for Ambulation</measure>
    <time_frame>6 months, 1 year, 2 year, 3 year, 4 year, 5 year - after the transplant</time_frame>
    <description>No Device Assistance Needed for Ambulation evaluated at 6 months, 1 year, 2 year, 3 year, 4 year, 5 year - after the transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disability Score: Expanded Disability Status Scale (EDSS)</measure>
    <time_frame>pretransplant 6 month, 5 year</time_frame>
    <description>Disability scores (disease improvement defined by at least a 1 point increase in the Expanded Disability Status Scale (EDSS) on consecutive evaluations at least three months apart.
The EDSS scale ranges from 0 to 10 in 0.5 unit increments that represent higher levels of disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NMO-IgG Aquaporin- 4 Autoantibody Titer</measure>
    <time_frame>Pretransplant and 5 year Post Transplant</time_frame>
    <description>NMO-IgG aquaporin- 4 autoantibody titer will be tested pretransplant and post transplant.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Devic's Disease</condition>
  <arm_group>
    <arm_group_label>Hematopoietic Stem Cell Transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hematopoietic stem cell transplantation will be performed after conditioning regimen of cyclophosphamide, G-CSF, Mesna, rATG, rituximab, and methylprednisolone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Infusion of participant's own stem cells</description>
    <arm_group_label>Hematopoietic Stem Cell Transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>A medication used as chemotherapy and to suppress the immune system</description>
    <arm_group_label>Hematopoietic Stem Cell Transplantation</arm_group_label>
    <other_name>Cytoxan</other_name>
    <other_name>Neosar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-CSF</intervention_name>
    <description>A glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream</description>
    <arm_group_label>Hematopoietic Stem Cell Transplantation</arm_group_label>
    <other_name>Neupogen</other_name>
    <other_name>Filgrastim</other_name>
    <other_name>Granix</other_name>
    <other_name>Zarxio</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rATG</intervention_name>
    <description>A rabbit polyclonal antibody to lymphocytes</description>
    <arm_group_label>Hematopoietic Stem Cell Transplantation</arm_group_label>
    <other_name>Thymoglobulin</other_name>
    <other_name>Anti-Thymocyte Globulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesna</intervention_name>
    <description>A medication used in those taking cyclophosphamide or ifosfamide to decrease the risk of bleeding from the bladder</description>
    <arm_group_label>Hematopoietic Stem Cell Transplantation</arm_group_label>
    <other_name>Mesnex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Monoclonal antibody therapy used to treat certain autoimmune diseases and types of cancer</description>
    <arm_group_label>Hematopoietic Stem Cell Transplantation</arm_group_label>
    <other_name>Rituxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>A corticosteroid medication used to suppress the immune system and decrease inflammation</description>
    <arm_group_label>Hematopoietic Stem Cell Transplantation</arm_group_label>
    <other_name>Solu-Medrol</other_name>
    <other_name>Depo-Medrol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 16-65, at the time of pretransplant evaluation

          -  An established diagnosis of Devic's disease (more than one acute attack)

          -  NMO- IgG aquaporin-4 autoantibody positive

        Exclusion Criteria:

          -  Paraplegia or quadriplegia and legal blindness (defined as visual acuity of 20/200 or
             less in the better eye with the best correction possible)

          -  Any illness that in the opinion of the investigators would jeopardize the ability of
             the patient to tolerate aggressive chemotherapy

          -  Prior history of malignancy except localized basal cell, squamous skin cancer or
             carcinoma in situ of the cervix. Other malignancies for which the patient is judged to
             be cured, such as head and neck cancer, or breast cancer will be considered on an
             individual basis

          -  Positive pregnancy test

          -  Inability or unwillingness to pursue effective means of birth control. Effective birth
             control is defined as 1) refraining from all acts of vaginal intercourse (ABSTINENCE);
             2) consistent use of birth control pills; 3) injectable birth control methods
             (Depo-provera, Norplant); 4) tubal sterilization or male partner who has undergone
             vasectomy; 5) placement of an intrauterine device (IUD); or 6) use, with every act of
             intercourse, of diaphragm with contraceptive jelly and/or condoms with contraceptive
             foam

          -  Failure to willingly accept or comprehend irreversible sterility as a side effect of
             therapy

          -  forced expiratory volume at one (FEV1) / forced vital capacity (FVC) &lt; 60% of
             predicted after bronchodilator therapy (if necessary)

          -  Diffusing capacity of lung for carbon monoxide (DLCO) &lt; 50% of predicted

          -  Resting left ventricular ejection fraction (LVEF) &lt; 50 %

          -  Serum creatinine &gt; 2.0 mg/dl

          -  Known hypersensitivity to mouse, rabbit, or E. Coli derived proteins

          -  Presence of metallic objects implanted in the body that would preclude the ability of
             the patient to safely have MRI exams

          -  Bilirubin &gt; 2.0 mg/dl

          -  Platelet count &lt; 100,000/ul or absolute neutrophil count (ANC) &lt; 1000/ul

          -  Psychiatric illness, mental deficiency or cognitive dysfunction making compliance with
             treatment or informed consent impossible

          -  Active infection except asymptomatic bacteriuria

          -  Inability to give informed consent

          -  HIV positive

          -  Transaminases &gt; 3x of normal limits, liver cirrhosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Burt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University, Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://n.neurology.org/content/93/18/e1732.long</url>
    <description>American Academy of Neurology</description>
  </link>
  <reference>
    <citation>Burt RK, Balabanov R, Han X, Burns C, Gastala J, Jovanovic B, Helenowski I, Jitprapaikulsan J, Fryer JP, Pittock SJ. Autologous nonmyeloablative hematopoietic stem cell transplantation for neuromyelitis optica. Neurology. 2019 Oct 29;93(18):e1732-e1741. doi: 10.1212/WNL.0000000000008394. Epub 2019 Oct 2.</citation>
    <PMID>31578302</PMID>
  </reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>October 31, 2008</study_first_submitted>
  <study_first_submitted_qc>November 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2008</study_first_posted>
  <results_first_submitted>November 18, 2019</results_first_submitted>
  <results_first_submitted_qc>February 17, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 28, 2020</results_first_posted>
  <last_update_submitted>February 17, 2020</last_update_submitted>
  <last_update_submitted_qc>February 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Richard Burt, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>High dose immunosuppressive therapy</keyword>
  <keyword>Hematopoietic stem cell support</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuromyelitis Optica</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 28, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/22/NCT00787722/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 28, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/22/NCT00787722/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Hematopoietic Stem Cell Transplantation</title>
          <description>Hematopoietic stem cell transplantation will be performed after conditioning regimen of cyclophosphamide, G-CSF, Mesna, rATG, rituximab, and methylprednisolone.
Hematopoietic Stem Cell Transplantation: Infusion of participant's own stem cells
Cyclophosphamide: A medication used as chemotherapy and to suppress the immune system
G-CSF: A glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
rATG: A rabbit polyclonal antibody to lymphocytes
Mesna: A medication used in those taking cyclophosphamide or ifosfamide to decrease the risk of bleeding from the bladder
Rituximab: Monoclonal antibody therapy used to treat certain autoimmune diseases and types of cancer
Methylprednisolone: A corticosteroid medication used to suppress the immune system and decrease inflammation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Hematopoietic Stem Cell Transplantation</title>
          <description>Hematopoietic stem cell transplantation will be performed after conditioning regimen of cyclophosphamide, G-CSF, Mesna, rATG, rituximab, and methylprednisolone.
Hematopoietic Stem Cell Transplantation: Infusion of participant's own stem cells
Cyclophosphamide: A medication used as chemotherapy and to suppress the immune system
G-CSF: A glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
rATG: A rabbit polyclonal antibody to lymphocytes
Mesna: A medication used in those taking cyclophosphamide or ifosfamide to decrease the risk of bleeding from the bladder
Rituximab: Monoclonal antibody therapy used to treat certain autoimmune diseases and types of cancer
Methylprednisolone: A corticosteroid medication used to suppress the immune system and decrease inflammation</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42" lower_limit="19" upper_limit="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Survival</title>
        <description>survival rate will be evaluated at 6 months,1 year, 2 year, 3 year, 4 year, 5 year after the transplant</description>
        <time_frame>6 months, 1 year, 2 year, 3 year, 4 year, 5 year - after the transplant</time_frame>
        <population>The reason that the number analyzed in one or more rows differs from the overall number analyzed is because one patient with coexistent SLE died of complications from active lupus 10 months after the transplant and another patient was only 3 years out from transplant.</population>
        <group_list>
          <group group_id="O1">
            <title>Hematopoietic Stem Cell Transplantation</title>
            <description>Hematopoietic stem cell transplantation will be performed after conditioning regimen of cyclophosphamide, G-CSF, Mesna, rATG, rituximab, and methylprednisolone.
Hematopoietic Stem Cell Transplantation: Infusion of participant's own stem cells
Cyclophosphamide: A medication used as chemotherapy and to suppress the immune system
G-CSF: A glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
rATG: A rabbit polyclonal antibody to lymphocytes
Mesna: A medication used in those taking cyclophosphamide or ifosfamide to decrease the risk of bleeding from the bladder
Rituximab: Monoclonal antibody therapy used to treat certain autoimmune diseases and types of cancer
Methylprednisolone: A corticosteroid medication used to suppress the immune system and decrease inflammation</description>
          </group>
        </group_list>
        <measure>
          <title>Survival</title>
          <description>survival rate will be evaluated at 6 months,1 year, 2 year, 3 year, 4 year, 5 year after the transplant</description>
          <population>The reason that the number analyzed in one or more rows differs from the overall number analyzed is because one patient with coexistent SLE died of complications from active lupus 10 months after the transplant and another patient was only 3 years out from transplant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 months survival</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year survival</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 year survival</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 year survival</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 year survival</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 year survival</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life (QOL) Short Form - 36 (SF-36)</title>
        <description>SF- 36 is a self-administered quality of life exam. The evaluation of the results was done by attributing scores to each question, which were then transformed into a scale ranging from 0 to 100, where 0 corresponds to the worst quality of life and 100 to the best.</description>
        <time_frame>pre-transplant 12mo and 5 years</time_frame>
        <population>The reason that the number analyzed differs in one or more rows is because 1 patient did not complete the form and was excluded. Another patient was not 5 years out from transplant so there is no 5 year data on the patient.</population>
        <group_list>
          <group group_id="O1">
            <title>Hematopoietic Stem Cell Transplantation</title>
            <description>Hematopoietic stem cell transplantation will be performed after conditioning regimen of cyclophosphamide, G-CSF, Mesna, rATG, rituximab, and methylprednisolone.
Hematopoietic Stem Cell Transplantation: Infusion of participant's own stem cells
Cyclophosphamide: A medication used as chemotherapy and to suppress the immune system
G-CSF: A glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
rATG: A rabbit polyclonal antibody to lymphocytes
Mesna: A medication used in those taking cyclophosphamide or ifosfamide to decrease the risk of bleeding from the bladder
Rituximab: Monoclonal antibody therapy used to treat certain autoimmune diseases and types of cancer
Methylprednisolone: A corticosteroid medication used to suppress the immune system and decrease inflammation</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life (QOL) Short Form - 36 (SF-36)</title>
          <description>SF- 36 is a self-administered quality of life exam. The evaluation of the results was done by attributing scores to each question, which were then transformed into a scale ranging from 0 to 100, where 0 corresponds to the worst quality of life and 100 to the best.</description>
          <population>The reason that the number analyzed differs in one or more rows is because 1 patient did not complete the form and was excluded. Another patient was not 5 years out from transplant so there is no 5 year data on the patient.</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pretransplant</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.83" spread="34.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Year Post Transplant</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.69" spread="55.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 Year Post Transplant</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.63" spread="62.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post HSCT Immune -Modulating Medication and Relapse</title>
        <description>Number of immune - modulating medication and relapse evaluated 5 year - after the transplant</description>
        <time_frame>Pre transplant and 6 months, 1 year, 2 year, 3 year, 4 year and 5 year after transplant</time_frame>
        <population>The reason that the number analyzed in one or more rows differs from the overall number analyzed is because one patient with coexistent SLE died of complications from active lupus 10 months after the transplant and another patient was only 3 years out from transplant.</population>
        <group_list>
          <group group_id="O1">
            <title>Hematopoietic Stem Cell Transplantation (HSCT)</title>
            <description>Hematopoietic stem cell transplantation will be performed after conditioning regimen of cyclophosphamide, G-CSF, Mesna, rATG, rituximab, and methylprednisolone.
Hematopoietic Stem Cell Transplantation: Infusion of participant's own stem cells
Cyclophosphamide: A medication used as chemotherapy and to suppress the immune system
G-CSF: A glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
rATG: A rabbit polyclonal antibody to lymphocytes
Mesna: A medication used in those taking cyclophosphamide or ifosfamide to decrease the risk of bleeding from the bladder
Rituximab: Monoclonal antibody therapy used to treat certain autoimmune diseases and types of cancer
Methylprednisolone: A corticosteroid medication used to suppress the immune system and decrease inflammation</description>
          </group>
        </group_list>
        <measure>
          <title>Post HSCT Immune -Modulating Medication and Relapse</title>
          <description>Number of immune - modulating medication and relapse evaluated 5 year - after the transplant</description>
          <population>The reason that the number analyzed in one or more rows differs from the overall number analyzed is because one patient with coexistent SLE died of complications from active lupus 10 months after the transplant and another patient was only 3 years out from transplant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre HSCT - Immunosuppression/Relapse Rate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Mos Post HSCT Immunosuppression/ Relapse Rate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Year Post HSCT Immunosuppression/Relapse Rate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Year Post HSCT Immunosuppression/Relapse Rate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Year Post HSCT Immunosuppression/Relapse Rate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Year Post HSCT Immunosuppression/Relapse Rate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 Year Post HSCT Immunosuppression Relapse Rate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Require No Device Assistance for Ambulation</title>
        <description>No Device Assistance Needed for Ambulation evaluated at 6 months, 1 year, 2 year, 3 year, 4 year, 5 year - after the transplant</description>
        <time_frame>6 months, 1 year, 2 year, 3 year, 4 year, 5 year - after the transplant</time_frame>
        <population>The reason that the number analyzed in one or more rows differs from the overall number analyzed is because one patient with coexistent SLE died of complications from active lupus 10 months after the transplant and another patient was only 3 years out from transplant.</population>
        <group_list>
          <group group_id="O1">
            <title>Hematopoietic Stem Cell Transplantation</title>
            <description>Hematopoietic stem cell transplantation will be performed after conditioning regimen of cyclophosphamide, G-CSF, Mesna, rATG, rituximab, and methylprednisolone.
Hematopoietic Stem Cell Transplantation: Infusion of participant's own stem cells
Cyclophosphamide: A medication used as chemotherapy and to suppress the immune system
G-CSF: A glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
rATG: A rabbit polyclonal antibody to lymphocytes
Mesna: A medication used in those taking cyclophosphamide or ifosfamide to decrease the risk of bleeding from the bladder
Rituximab: Monoclonal antibody therapy used to treat certain autoimmune diseases and types of cancer
Methylprednisolone: A corticosteroid medication used to suppress the immune system and decrease inflammation</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Require No Device Assistance for Ambulation</title>
          <description>No Device Assistance Needed for Ambulation evaluated at 6 months, 1 year, 2 year, 3 year, 4 year, 5 year - after the transplant</description>
          <population>The reason that the number analyzed in one or more rows differs from the overall number analyzed is because one patient with coexistent SLE died of complications from active lupus 10 months after the transplant and another patient was only 3 years out from transplant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre HSCT- No Assistive Required</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Mos Post HSCT- No Assistive Device Required</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Year Post HSCT- No Assistive Device Required</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Year Post HSCT- No Assistive Device Required</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Year Post HSCT- No Assistive Device Required</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Year Post HSCT- No Assistive Device Required</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 Year Post HSCT- No Assistive Device Required</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disability Score: Expanded Disability Status Scale (EDSS)</title>
        <description>Disability scores (disease improvement defined by at least a 1 point increase in the Expanded Disability Status Scale (EDSS) on consecutive evaluations at least three months apart.
The EDSS scale ranges from 0 to 10 in 0.5 unit increments that represent higher levels of disability.</description>
        <time_frame>pretransplant 6 month, 5 year</time_frame>
        <population>The reason that the number analyzed in one or more rows differs from the overall number analyzed is because one patient with coexistent SLE died of complications from active lupus 10 months after the transplant and another patient was only 3 years out from transplant.</population>
        <group_list>
          <group group_id="O1">
            <title>Hematopoietic Stem Cell Transplantation</title>
            <description>Hematopoietic stem cell transplantation will be performed after conditioning regimen of cyclophosphamide, G-CSF, Mesna, rATG, rituximab, and methylprednisolone.
Hematopoietic Stem Cell Transplantation: Infusion of participant's own stem cells
Cyclophosphamide: A medication used as chemotherapy and to suppress the immune system
G-CSF: A glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
rATG: A rabbit polyclonal antibody to lymphocytes
Mesna: A medication used in those taking cyclophosphamide or ifosfamide to decrease the risk of bleeding from the bladder
Rituximab: Monoclonal antibody therapy used to treat certain autoimmune diseases and types of cancer
Methylprednisolone: A corticosteroid medication used to suppress the immune system and decrease inflammation</description>
          </group>
        </group_list>
        <measure>
          <title>Disability Score: Expanded Disability Status Scale (EDSS)</title>
          <description>Disability scores (disease improvement defined by at least a 1 point increase in the Expanded Disability Status Scale (EDSS) on consecutive evaluations at least three months apart.
The EDSS scale ranges from 0 to 10 in 0.5 unit increments that represent higher levels of disability.</description>
          <population>The reason that the number analyzed in one or more rows differs from the overall number analyzed is because one patient with coexistent SLE died of complications from active lupus 10 months after the transplant and another patient was only 3 years out from transplant.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pretransplant Disability Score (EDSS)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" lower_limit="2.0" upper_limit="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Year Post Transplant Disability Score (EDSS)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" lower_limit="1" upper_limit="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 Year Post Transplant Disability Score (EDSS)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" lower_limit="0" upper_limit="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>NMO-IgG Aquaporin- 4 Autoantibody Titer</title>
        <description>NMO-IgG aquaporin- 4 autoantibody titer will be tested pretransplant and post transplant.</description>
        <time_frame>Pretransplant and 5 year Post Transplant</time_frame>
        <population>The reason that the number analyzed in one or more rows differs from the overall number analyzed is because one patient with coexistent SLE died of complications from active lupus 10 months after the transplant and another patient was only 3 years out from transplant.</population>
        <group_list>
          <group group_id="O1">
            <title>Hematopoietic Stem Cell Transplantation</title>
            <description>Hematopoietic stem cell transplantation will be performed after conditioning regimen of cyclophosphamide, G-CSF, Mesna, rATG, rituximab, and methylprednisolone.
Hematopoietic Stem Cell Transplantation: Infusion of participant's own stem cells
Cyclophosphamide: A medication used as chemotherapy and to suppress the immune system
G-CSF: A glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
rATG: A rabbit polyclonal antibody to lymphocytes
Mesna: A medication used in those taking cyclophosphamide or ifosfamide to decrease the risk of bleeding from the bladder
Rituximab: Monoclonal antibody therapy used to treat certain autoimmune diseases and types of cancer
Methylprednisolone: A corticosteroid medication used to suppress the immune system and decrease inflammation</description>
          </group>
        </group_list>
        <measure>
          <title>NMO-IgG Aquaporin- 4 Autoantibody Titer</title>
          <description>NMO-IgG aquaporin- 4 autoantibody titer will be tested pretransplant and post transplant.</description>
          <population>The reason that the number analyzed in one or more rows differs from the overall number analyzed is because one patient with coexistent SLE died of complications from active lupus 10 months after the transplant and another patient was only 3 years out from transplant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pretransplant NMO ASSAY positive</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 year post transplant NMO Assay positive</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Hematopoietic Stem Cell Transplantation</title>
          <description>Hematopoietic stem cell transplantation will be performed after conditioning regimen of cyclophosphamide, G-CSF, Mesna, rATG, rituximab, and methylprednisolone.
Hematopoietic Stem Cell Transplantation: Infusion of participant's own stem cells
Cyclophosphamide: A medication used as chemotherapy and to suppress the immune system
G-CSF: A glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
rATG: A rabbit polyclonal antibody to lymphocytes
Mesna: A medication used in those taking cyclophosphamide or ifosfamide to decrease the risk of bleeding from the bladder
Rituximab: Monoclonal antibody therapy used to treat certain autoimmune diseases and types of cancer
Methylprednisolone: A corticosteroid medication used to suppress the immune system and decrease inflammation</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Unrelated Complications from Systemic Lupus Erythematosus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenic Fevers</sub_title>
                <description>Neutropenic Fevers</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Orthostatic Hypotension</sub_title>
                <description>orthostatic hypotension</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypertension, Hyperglycemia, Diarrhea</sub_title>
                <description>hypertension, hyperglycemia and diarrhea</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <description>C.Diff</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <description>hypophosphatemia</description>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <description>hypocalcemia</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Nausea and Vomiting</sub_title>
                <description>nausea and vomiting</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <description>hypokalemia</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kathleen Quigley</name_or_title>
      <organization>Northwestern University</organization>
      <phone>312-695-8192</phone>
      <email>k-quigley@northwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

